P38β MAPK upregulates atrogin1/MAFbx by specific phosphorylation of C/EBPβ

Skeletal Muscle

Volumn 2, Issue 1, 2012, Pages

  Zhang, Guohua ^a   Li, Yi Ping ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cachexia; DNA binding; E3 protein; Gene regulation; Thr 188

Indexed keywords

EID: 84871883139     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-2-20     Document Type: Article

References (42)

1. Tremblay F, Dubois MJ, Marette A. Regulation of GLUT4 traffic and function by insulin and contraction in skeletal muscle. Front Biosci 2003, 8:d1072-d1084. 10.2741/1137, 12957810.
2. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004, 279:17070-17078. 10.1074/jbc.M312021200, 14764603.
3. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005, 19:362-370. 10.1096/fj.04-2364com, 3099533, 15746179.
4. Doyle A, Zhang G, Abdel Fattah EA, Eissa NT, Li YP. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J 2011, 25:99-110. 10.1096/fj.10-164152, 3005430, 20826541.
5. McClung JM, Judge AR, Powers SK, Yan Z. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010, 298:C542-C549. 10.1152/ajpcell.00192.2009, 2838571, 19955483.
6. Long YC, Widegren U, Zierath JR. Exercise-induced mitogen-activated protein kinase signalling in skeletal muscle. Proc Nutr Soc 2004, 63:227-232. 10.1079/PNS2004346, 15294035.
7. Jones NC, Tyner KJ, Nibarger L, Stanley HM, Cornelison DD, Fedorov YV, Olwin BB. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol 2005, 169:105-116. 10.1083/jcb.200408066, 2171902, 15824134.
8. Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 2006, 16:36-44. 10.1016/j.tcb.2005.11.002, 16325404.
9. Remy G, Risco AM, Inesta-Vaquera FA, Gonzalez-Teran B, Sabio G, Davis RJ, Cuenda A. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 2010, 22:660-667. 10.1016/j.cellsig.2009.11.020, 20004242.
10. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998, 273:1741-1748. 10.1074/jbc.273.3.1741, 9430721.
11. Loesch M, Chen G. The p38 MAPK stress pathway as a tumor suppressor or more?. Front Biosci 2008, 13:3581-3593.
12. Perdiguero E, Ruiz-Bonilla V, Gresh L, Hui L, Ballestar E, Sousa-Victor P, Baeza-Raja B, Jardi M, Bosch-Comas A, Esteller M, Caelles C, Serrano AL, Wagner EF, Munoz-Canoves P. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J 2007, 26:1245-1256. 10.1038/sj.emboj.7601587, 1817635, 17304211.
13. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, Sartorelli V, Puri PL. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010, 7:455-469. 10.1016/j.stem.2010.08.013, 2951277, 20887952.
14. Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, Seale V, Cuenda A, Ranish JA, Rudnicki MA. p38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program. J Cell Biol 2009, 187:991-1005. 10.1083/jcb.200907037, 2806273, 20026657.
15. Pogozelski AR, Geng T, Li P, Yin X, Lira VA, Zhang M, Chi JT, Yan Z. p38gamma mitogen-activated protein kinase is a key regulator in skeletal muscle metabolic adaptation in mice. PLoS One 2009, 4:e7934. 10.1371/journal.pone.0007934, 2775956, 19936205.
16. Ho RC, Alcazar O, Fujii N, Hirshman MF, Goodyear LJ. p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2004, 286:R342-R349.
17. Zhang G, Jin B, Li YP. C/EBPbeta mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO J 2011, 30:4323-4335. 10.1038/emboj.2011.292, 3199382, 21847090.
18. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr 2008, 27:793-799. 10.1016/j.clnu.2008.06.013, 18718696.
19. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009, 89:381-410. 10.1152/physrev.00016.2008, 19342610.
20. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006, 17:1807-1819. 10.1681/ASN.2006010083, 16738015.
21. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412. 10.1016/S0092-8674(04)00400-3, 15109499.
22. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403. 10.1016/S1097-2765(04)00211-4, 15125842.
23. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 2007, 21:140-155.
24. Penna F, Bonetto A, Muscaritoli M, Costamagna D, Minero VG, Bonelli G, Rossi Fanelli F, Baccino FM, Costelli P. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?. Int J Cancer 2010, 127(7):1706-1717. 10.1002/ijc.25146, 20039316.
25. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298. 10.1016/j.cell.2004.09.027, 15479644.
26. Askari N, Beenstock J, Livnah O, Engelberg D. p38 is active in vitro and in vivo when monophosphorylated on Thr180. Biochemistry 2009, 48:2497-2504. 10.1021/bi900024v, 19209848.
27. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci USA 2005, 102:5679-5684. 10.1073/pnas.0502067102, 556302, 15824322.
28. Sterneck E, Tessarollo L, Johnson PF. An essential role for C/EBPbeta in female reproduction. Genes Dev 1997, 11:2153-2162. 10.1101/gad.11.17.2153, 275394, 9303532.
29. Williams SC, Baer M, Dillner AJ, Johnson PF. CRP2 (C/EBP beta) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity. EMBO J 1995, 14:3170-3183. 394378, 7621830.
30. Lee S, Miller M, Shuman JD, Johnson PF. CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP). J Biol Chem 2010, 285:21399-21410. 10.1074/jbc.M110.128413, 2898398, 20452968.
31. Tang QQ, Gronborg M, Huang H, Kim JW, Otto TC, Pandey A, Lane MD. Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis. Proc Natl Acad Sci USA 2005, 102:9766-9771. 10.1073/pnas.0503891102, 1175002, 15985551.
32. Li X, Kim JW, Gronborg M, Urlaub H, Lane MD, Tang QQ. Role of cdk2 in the sequential phosphorylation/activation of C/EBPbeta during adipocyte differentiation. Proc Natl Acad Sci USA 2007, 104:11597-11602. 10.1073/pnas.0703771104, 1913868, 17601773.
33. Kim JW, Tang QQ, Li X, Lane MD. Effect of phosphorylation and S-S bond-induced dimerization on DNA binding and transcriptional activation by C/EBPbeta. Proc Natl Acad Sci USA 2007, 104:1800-1804. 10.1073/pnas.0611137104, 1794285, 17264204.
34. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998, 273:32111-32120. 10.1074/jbc.273.48.32111, 9822687.
35. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009, 15:369-379. 10.1016/j.molmed.2009.06.005, 3016890, 19665431.
36. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B, Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320:667-670. 10.1126/science.1156037, 2597039, 18451303.
37. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996, 271:17920-17926. 10.1074/jbc.271.30.17920, 8663524.
38. O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, Chen SL, Lowitz K, Rasa C, Visco D, Luell S, Carballo-Jane E, Owens K, Zaller DM. Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. J Biol Chem 2007, 282:34663-34671. 10.1074/jbc.M704236200, 17855341.
39. Sicard P, Clark JE, Jacquet S, Mohammadi S, Arthur JS, O'Keefe SJ, Marber MS. The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning. J Mol Cell Cardiol 2010, 48:1324-1328. 10.1016/j.yjmcc.2010.02.013, 2877771, 20188737.
40. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002, 365:561-575. 1222736, 12006103.
41. Bostrom P, Mann N, Wu J, Quintero PA, Plovie ER, Panakova D, Gupta RK, Xiao C, MacRae CA, Rosenzweig A, Spiegelman BM. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 2010, 143:1072-1083. 10.1016/j.cell.2010.11.036, 3035164, 21183071.
42. Guo S, Cichy SB, He X, Yang Q, Ragland M, Ghosh AK, Johnson PF, Unterman TG. Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta. J Biol Chem 2001, 276:8516-8523. 10.1074/jbc.M008542200, 11116148.